Azitra Taps Microbiome For Dermatology Therapies, Including Cancer Supportive Care

Emerging Company Profile: Based on its founders’ research at Yale, Azitra is developing topical therapies to treat skin dysbiosis associated with chemotherapy as well as two approaches to atopic dermatitis.

Emerging Company Profile Regular column feature image Version 2

Azitra Inc. is nearing the clinic with its initial two programs based on harnessing the microbiome to address dermatological conditions, but the privately held company also has a second potential stream of income through a partnership inked in 2019 with Bayer AG to apply its technology to cosmetics.

Founded in 2014 and based on research performed at Yale University by co-founder Travis Whitfill, now the biotech’s executive...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Start-Ups & SMEs

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.